BPC-157 / TB500 20mg

Description

BPC-157 / TB500 20mg

BPC-157/TB-500 Combination 10mg

This dual-peptide formulation includes 10mg of BPC-157 and 10mg of TB-500, resulting in a synergistic 10mg lyophilized blend. These peptides are frequently studied for their regenerative and anti-inflammatory properties. Together, they are commonly used in research focused on accelerating healing, supporting musculoskeletal recovery, and enhancing cellular repair mechanisms.

BPC-157/TB-500 Research Based Benefits

• May assist in studies on soft tissue regeneration and wound healing
• Known for potential anti-inflammatory activity in tendon, muscle, and ligament research
• Could support angiogenesis and blood flow studies related to recovery
• May benefit research on gastrointestinal repair and systemic healing
• Useful in examining synergistic cellular regeneration pathways

Molecular Formulas

• BPC-157: C62H98N16O22

• TB-500: C212H350N56O78S

Product Features

• Total 10mg lyophilized powder: 10mg BPC-157 + 10mg TB-500
• Research-grade dual peptide blend for advanced scientific study
• Convenient single-vial formulation for efficient use
• Ideal for studies focused on recovery, inflammation, and tissue healing
• Securely packaged for safe handling and stability

BPC‑157

Preclinical Healing & Regeneration Studies:

• Tendon healing (rats): Accelerated outgrowth of tendon fibroblasts, improved cell survival and migration via FAK-paxillin pathway in Achilles tendon explants
• Nerve & soft tissue recovery (rodents): Improved functional recovery and neuroprotection in sciatic nerve transection and brain injury models
• Mechanistic overview: MDPI review emphasizes its angiogenic, anti-inflammatory, and safety profiles across diverse preclinical injury models

TB‑500

Wound Healing & Regeneration Evidence:

• Skin wound model: Topical or IP Tβ4 increased re-epithelialization by 42–61% and collagen deposition in full-thickness wounds
• Dermal repair across models: Accelerated healing in steroid-treated, diabetic, and aged rodents via enhanced tissue regeneration
• Clinical phase II: Improved healing in pressure ulcers, stasis ulcers, and epidermolysis bullosa patients
• Recent white paper summary: Acceleration of wound closure, tissue regeneration, and corneal/diabetic wound improvements described

Safety Disclaimer

This product is intended for research purposes only. It is not intended for human consumption or medical use.